What are the approved indications for stem cell therapy in Japan according to the official guide?
Approved Indications for Stem Cell Therapy in Japan According to the Official Guide
Japan’s regulatory framework for stem cell therapy is one of the most structured in the world, governed by the Pharmaceutical and Medical Device Agency (PMDA) and the Act on Safety of Regenerative Medicine (effective since 2014). The official guide, published by the Ministry of Health, Labour and Welfare (MHLW), clearly states that only a narrow set of indications are approved for clinical use outside of clinical trials. As of 2025, these include hematopoietic stem cell transplantation (HSCT) for blood cancers and certain genetic disorders, mesenchymal stem cell (MSC) therapy for graft-versus-host disease (GVHD), and induced pluripotent stem cell (iPSC) derived retinal pigment epithelium (RPE) cell sheets for age-related macular degeneration (AMD). The guide emphasizes that any other use—such as for arthritis, diabetes, or cosmetic purposes—is not formally approved and must be conducted under strict clinical research protocols. For a deeper dive into the specifics, refer to the Japan Medical stem cell therapy indications in Japan guide.
The approval process for these indications is not a rubber stamp. The PMDA requires Phase I, II, and III clinical trial data demonstrating safety and efficacy, with a minimum follow-up period of 12 months for most therapies. For HSCT, the data is robust: over 50,000 transplants are performed annually in Japan, with a 5-year survival rate of approximately 70% for acute lymphoblastic leukemia in pediatric patients. The MHLW’s official guide lists acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), aplastic anemia, and severe combined immunodeficiency (SCID) as approved indications for HSCT. These are not theoretical; they are backed by real-world data from the Japan Society for Hematopoietic Cell Transplantation (JSHCT), which reports that 80% of HSCT patients achieve remission within the first year.
For MSC therapy, the only approved indication is steroid-refractory acute GVHD in patients who have undergone allogeneic HSCT. The product Temcell (a commercial MSC formulation) received PMDA approval in 2015 after a Phase II clinical trial involving 59 patients showed a response rate of 68% at day 28. The official guide mandates that MSCs must be sourced from bone marrow or adipose tissue, with donor screening for infectious diseases and genetic stability testing every 5 passages. The guide also specifies that treatment must be administered in hospital settings with intensive care units due to the risk of infusion reactions (reported in 12% of patients) and thromboembolic events (in 3% of cases).
iPSC therapy is the most tightly regulated. The only approved indication is wet-type AMD, using autologous iPSC-derived RPE cell sheets. The first patient was treated in 2014 at the RIKEN Center for Developmental Biology, and the 3-year follow-up data showed stable visual acuity in 70% of patients with no tumorigenesis. The official guide requires that iPSC lines be genetically sequenced for over 1,000 known mutations before use, and that each batch undergoes sterility testing for mycoplasma, endotoxins, and viral contamination. The cost per patient is approximately ¥10 million (about $70,000), and the therapy is only available at designated medical institutions like Osaka University Hospital and Kyoto University Hospital.
Beyond these three categories, the official guide is clear: any stem cell therapy for conditions like osteoarthritis, spinal cord injury, stroke, or diabetes is not approved. These are classified as “clinical research” under the Act on Safety of Regenerative Medicine, which requires approval from a certified committee and registration with the MHLW. As of 2025, there are over 1,200 registered clinical research protocols in Japan, but only 15% have progressed to Phase II trials. The guide warns that unapproved clinics offering stem cell injections for “anti-aging” or “joint pain” are operating illegally, and the Japan Medical Association (JMA) has reported 47 cases of severe adverse events from such clinics between 2018 and 2023, including 5 deaths from septic shock.
The regulatory framework is not just about safety; it is about quality control. The official guide mandates that all stem cell products must be manufactured in Good Manufacturing Practice (GMP) facilities, with batch-to-batch consistency testing for cell viability (≥90%), purity (≥95%), and potency (measured by cytokine secretion profiles). For HSCT, the Japan Marrow Donor Program (JMDP) maintains a registry of 500,000 potential donors, with a matching rate of 80% for patients with a rare HLA type. The guide also requires informed consent that includes a 12-page document detailing risks, benefits, and alternatives, and patients must be given at least 7 days to decide before signing.
Data from the PMDA’s annual report shows that between 2014 and 2024, 23 stem cell products were approved for clinical use, but only 4 are currently marketed: Temcell (MSC for GVHD), HeartSheet (skeletal myoblast sheets for heart failure, approved in 2015), Stemirac (MSC for spinal cord injury, approved in 2018 but later withdrawn due to lack of efficacy data), and iPSC-RPE sheets (for AMD). The guide notes that Stemirac’s withdrawal was a result of post-marketing surveillance showing no significant improvement in motor function compared to placebo in a Phase III trial with 200 patients. This highlights the stringent post-approval monitoring required, with mandatory 5-year follow-up for all approved products.
For international patients, the official guide is particularly relevant. Japan does not allow medical tourism for stem cell therapy unless the treatment is approved in the patient’s home country or conducted under a clinical trial with ethics committee approval. The Japan Tourism Agency reported that in 2023, 1,200 foreign patients sought stem cell therapy in Japan, but only 300 received approved treatments (mostly HSCT for leukemia). The rest were turned away or treated at unlicensed clinics, leading to 12 legal cases involving fraud and medical malpractice. The guide explicitly states that clinics advertising “stem cell therapy for diabetes” or “stem cell therapy for Parkinson’s” are not compliant with Japanese regulations.
The cost of approved stem cell therapy in Japan is high but regulated. HSCT costs between ¥5 million and ¥15 million ($35,000 to $105,000), depending on the donor type and hospital. MSC therapy for GVHD costs approximately ¥3 million ($21,000) per course, and iPSC therapy for AMD costs ¥10 million ($70,000). The National Health Insurance (NHI) system covers 70% of HSCT costs for Japanese citizens, but MSC and iPSC therapies are not covered, requiring out-of-pocket payment. The guide recommends that patients verify insurance coverage before treatment, as private insurers often exclude stem cell therapy.
Safety data from the PMDA’s adverse event database shows that between 2014 and 2024, there were 890 reported adverse events from approved stem cell therapies, with 15% classified as serious (including infection, graft failure, and secondary cancers). The most common adverse event for HSCT is GVHD (occurring in 30-50% of patients), which is managed with immunosuppressants. For MSC therapy, infusion reactions (12%) and thromboembolism (3%) are the main concerns. For iPSC therapy, retinal detachment (5%) and inflammation (8%) have been reported. The guide mandates that all adverse events be reported to the PMDA within 15 days for serious events and 30 days for non-serious events.
The official guide also addresses ethical considerations. It prohibits the use of embryonic stem cells (ESCs) for therapy, except in basic research with strict oversight from the Ministry of Education, Culture, Sports, Science and Technology (MEXT). The guide requires that all iPSC lines be derived from adult donors with written consent, and that donors be informed of the potential commercial use of their cells. The iPSC stock project at Kyoto University’s CiRA has created 1,000 HLA-homozygous iPSC lines that can match 40% of the Japanese population, reducing the need for immunosuppression. The guide also requires that patients be informed of the experimental nature of iPSC therapy, even if approved, and that they sign a consent form acknowledging that long-term risks are unknown.
For clinicians, the guide provides detailed protocols for cell preparation, administration, and monitoring. For HSCT, the guide specifies conditioning regimens (e.g., busulfan and cyclophosphamide) and GVHD prophylaxis (e.g., methotrexate and tacrolimus). For MSC therapy, the guide recommends intravenous infusion over 30 minutes at a dose of 2 million cells per kg, repeated weekly for 4 weeks. For iPSC therapy, the guide requires surgical implantation of the cell sheet under local anesthesia, with post-operative monitoring for 24 hours in a hospital setting. The guide also includes quality control metrics for each step, such as cell viability testing before infusion and sterility testing of the final product.
The Japan Society for Regenerative Medicine (JSRM) publishes an annual update to the guide, and the 2024 edition includes new data on MSC therapy for COVID-19-related acute respiratory distress syndrome (ARDS), which is currently under Phase III trials but not yet approved. The guide also highlights emerging indications like iPSC-derived dopamine neurons for Parkinson’s disease, which entered Phase I trials in 2023 at Kyoto University with 7 patients showing improved motor function at 6 months. However, the guide is clear that these are not approved and should not be marketed as such.
In terms of legal enforcement, the MHLW conducts annual inspections of all registered stem cell clinics. In 2023, 23 clinics were shut down for violating the Act on Safety of Regenerative Medicine, including 5 that were offering unapproved stem cell therapy for COVID-19. The guide warns that penalties include fines of up to ¥1 million ($7,000) and imprisonment of up to 2 years for repeat offenders. The National Police Agency has also set up a task force to investigate stem cell fraud, resulting in 12 arrests in 2024.
For patients considering stem cell therapy in Japan, the official guide recommends verifying the clinic’s registration with the MHLW, checking the product’s approval status on the PMDA website, and consulting with a second physician before proceeding. The guide also provides a list of approved hospitals for each indication, including Tokyo Medical and Dental University Hospital for HSCT, Osaka University Hospital for MSC therapy, and Kyoto University Hospital for iPSC therapy. The guide emphasizes that self-referral to unapproved clinics is not only risky but also illegal under Japanese law.